CN102697822A - Application of sargentg loryvine stem active fraction to preparation of anti-inflammatory-immune and anti-ageing medicaments - Google Patents
Application of sargentg loryvine stem active fraction to preparation of anti-inflammatory-immune and anti-ageing medicaments Download PDFInfo
- Publication number
- CN102697822A CN102697822A CN2012101807818A CN201210180781A CN102697822A CN 102697822 A CN102697822 A CN 102697822A CN 2012101807818 A CN2012101807818 A CN 2012101807818A CN 201210180781 A CN201210180781 A CN 201210180781A CN 102697822 A CN102697822 A CN 102697822A
- Authority
- CN
- China
- Prior art keywords
- water
- caulis sargentodoxae
- water soluble
- ethyl acetate
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of a sargentg loryvine stem active fraction to preparation of anti-inflammatory-immune and anti-ageing medicaments, which belongs to the technical field of medicine. A method for applying the sargentg loryvine stem active fraction comprises the following steps of: performing reflux extraction on sargentg loryvine stem with water, and precipitating with ethanol to obtain sargentg loryvine stem polysaccharides and water-soluble fractions; and performing reflux extraction on sargentg loryvine stem with 50-80 percent ethanol, gradually leaching with petroleum ether, methylene dichloride and ethyl acetate in sequence to obtain a petroleum ether fraction, a methylene dichloride fraction and an ethyl acetate fraction, and treating a residual water phase with a macroporous adsorption resin HP-20 to obtain a water-soluble fraction. As proved by pharmacodynamics experimental research, the four fractions have remarkable inhibiting effects on xylene-caused mouse ear edema and carrageenan-caused rat paw edema, and the contents of MDA (Methane Dicarboxylic Aldehyde) and PGE2 (Phenyl Glycidyl Ether 2) in voix pedis inflammation tissues can be lowered. The four fractions have high in-vitro antioxidant activity, the content of MDA in blood serum and liver tissues can be lowered effectively, and the SOD (Super Oxygen Dehydrogenises) activity is increased. The sargentg loryvine stem active fraction can be applied to preparation of anti-inflammatory-immune medicaments and anti-ageing medicaments.
Description
Technical field
The invention belongs to medical technical field, be specifically related to from the Chinese crude drug Caulis Sargentodoxae, prepare position with anti inflammatory immunity activity and activity of fighting against senium, and the application aspect preparation anti inflammatory immunity medicine and antiaging agent.
Background technology
Caulis Sargentodoxae is Sargentodoxaceae plant Caulis Sargentodoxae Sargentodoxa cuneata (Oliv.) Rehd.et Wils. ratan.Have effects such as removing toxicity for eliminating carbuncles, promoting blood circulation and stopping pain, expelling wind and removing dampness, clinically separately or prescription in order to diseases such as treatment traumatic injury, rheumatic arthritis.Recent study finds that Caulis Sargentodoxae mainly contains chemical constituents such as phenols, organic acid, lignanoid, triterpene saponin, flavone, anthraquinone.Modern pharmacology research shows that Caulis Sargentodoxae extract or chemical compound have biological activitys such as protection cardiovascular system, antiviral, antitumor, antibiotic, antioxidation.
The Caulis Sargentodoxae water decoction shows immunosuppressive action in mouse model; Can reduce phagocytic index, IgM growing amount, periphery blood T lymphocyte number and T, the bone-marrow-derived lymphocyte conversion ratio of mice; To the cellular immunization of the T cell mediated of mice and all inhibited (Li Li of humoral immunization of bone-marrow-derived lymphocyte mediation; Deng. Chinese Journal of Immunology .2009,25 (3), 223-224).Caulis Sargentodoxae decocting liquid obviously reduce rat synovial membrane matrix metalloproteinase MMP-2 and MMP-9 expression (pay treasure, etc. Guizhou medicine .2009,33 (12), 1097-1099).Two kinds of phenol property glucosides in the Caulis Sargentodoxae have the activity of obvious inhibition sheep gonad prostaglandin synthetase, and have tangible anti-inflammatory activity (JP 06199885. for Sakakibara I, et al.).
Caulis Sargentodoxae is as a kind of conventional Chinese medicine, and no obvious toxic-side effects is clinical safe in utilization, is suitable for doing further research and development.The research of this medical material aspect anti inflammatory immunity at present is main with medical material water decoction and individual compound, does not still have the report that Caulis Sargentodoxae extract further is refined to active site and is used to prepare the anti inflammatory immunity medicine.Research and the application aspect defying age of Caulis Sargentodoxae extract and active site do not appear in the newspapers yet.
The application potential of active for the anti inflammatory immunity of testing and assess Caulis Sargentodoxae active site of the present invention in defying age aspect has used method well-known to those skilled in the art to test the biological activity at each position of medical material.These known method of testings comprise that mice caused by dimethylbenzene xylene ear swelling method of testing, carrageenin cause the rat paw edema method of testing; And inside and outside antioxidation model etc.; The result shows that selected Caulis Sargentodoxae active site has anti inflammatory immunity activity preferably; In the antioxidation model better activity is arranged all in vivo and in vitro, show good defying age application potential.
Summary of the invention
The purpose of this invention is to provide the effective site that Caulis Sargentodoxae has anti inflammatory immunity activity and defying age application potential.
Caulis Sargentodoxae polysaccharide, water soluble part W are confirmed through anti-inflammatory activity screening widely in each position of Caulis Sargentodoxae extract
1Ethyl acetate extraction position and water soluble part W with Caulis Sargentodoxae 50%-80% ethanol extraction
2Have remarkable inhibition mice caused by dimethylbenzene xylene ear swelling and carrageenin and cause the rat paw edema effect; It is active to demonstrate good anti inflammatory immunity; And in removing the experiment of DPPH free radical and reducing power, show the good in-vitro antioxidant activity, can significantly reduce malonaldehyde in serum and the liver organization (MDA) content, and increase superoxide dismutase (SOD) activity; The extract that shows Caulis Sargentodoxae has good inside and outside antioxidation, has antidotal potentiality.
Therefore, first aspect of the present invention relates to provides four kinds of active sites of Caulis Sargentodoxae and preparation method thereof:
Caulis Sargentodoxae polysaccharide (HT
PS) and water soluble part W
1(HT
W1) method for preparing, carry out according to following step: dry Caulis Sargentodoxae medical material, be crushed to 20 order coarse powder, powder is 100 ℃ of following water reflux, extract, twice, each 3 hours, behind the extracting solution concentrating under reduced pressure, adds dehydrated alcohol, the deposition of spending the night under 4 ℃-20 ℃, preferred 5-15 ℃; The centrifugal 10-30min of 3000r/min, preferred 15-20min; Drying precipitated part gets Caulis Sargentodoxae polysaccharide (HT
PS); The 1/30-1/5 of concentrated supernatant to original volume preferably is concentrated into the 1/20-1/10 of original volume; Cross the HP-20 macroporous adsorbent resin, first water is washed till closely colourless, reuse 2BV-10BV 80% (v/v) ethanol elution, preferred 4BV-6BV; Flow velocity is 10-60mL/min, preferred 20-30mL/min; Collect 80% ethanol (v/v) eluent, concentrate, lyophilization gets water soluble part W
1(HT
W1).
Caulis Sargentodoxae ethyl acetate extract (HT
AE) and water soluble part W
2(HT
W2) method for preparing, carry out according to following step: add 8-12 50%-80% alcohol reflux doubly in the Caulis Sargentodoxae medicinal powder, and filtered and recycled ethanol.The Caulis Sargentodoxae ethanol extraction is used aqueous dispersion, uses petroleum ether, dichloromethane, ethyl acetate fractional extraction successively, and concentrating under reduced pressure reclaims solvent, obtains petroleum ether part, dichloromethane position, ethyl acetate extract (HT respectively
AE), the water position.The water position is concentrated into the 1/30-1/10 of original volume, preferably is concentrated into the 1/20-1/15 of original volume; Cross the HP-20 macroporous adsorbent resin, first water is washed till closely colourless, reuse 2BV-10BV 95% (v/v) ethanol elution, preferred 4BV-6BV; Flow velocity is 10-60mL/min, preferred 20-30mL/min; Collect 95% ethanol elution, concentrate water soluble part W
2(HT
W2).
Second aspect of the present invention relates to the purposes that said four positions is used to prepare anti inflammatory immunity and antiaging agent.Observation sample xylol under various dose causes that mice ear, carrageenin cause the rat paw edema degree, carrageenin causes prostaglandin (PGE in the rat paw inflammatory tissue respectively
2) and the influence of malonaldehyde (MDA) content.The result shows that four active sites of Caulis Sargentodoxae all have significant anti inflammatory immunity activity, can be used for preparing the medicine of treatment inflammatory disease such as diseases such as rheumatism or rheumatoid arthritis.Simultaneously in external model, have obvious antioxidation activity, and can significantly reduce MDA content in serum and the liver organization, and it is active to increase SOD, show that the Caulis Sargentodoxae active site has good potentiality aspect the preparation antiaging agent.
Third aspect of the present invention relates to the pharmaceutical composition that provides Caulis Sargentodoxae active site and acceptable accessories to form.
The Caulis Sargentodoxae active site can be independent or several kinds of positions combinations, more further with the adjuvant combination, dosage form comprises: tablet, capsule, unguentum, patch, injection etc.
Carrier of the present invention or excipient comprise the conventional application carrier of pharmaceutics and excipient, for example filler, binding agent, antiseptic, correctives, diluent, coloring agent etc.
Below embodiment and biological activity test be to further explain of the present invention, below cited embodiment constitute restriction never in any form.
The specific embodiment
Embodiment 1
Caulis Sargentodoxae polysaccharide (HT
PS) and water soluble part W
1(HT
W1) preparation:
Get 70g and be ground into the dry Caulis Sargentodoxae stem about 20 orders, measure pure water reflux, extract, twice with 8 times down for 100 ℃, each 3 hours, merge extractive liquid, was evaporated to 200mL, added dehydrated alcohol to 1000mL, put 4 ℃ of refrigerator overnight depositions, and is centrifugal, the drying precipitated HT that gets
PS2.8g; Concentrated supernatant is crossed the HP-20 macroporous adsorbent resin, and first water is washed till no saccharide material, and reuse 80% ethanol is washed till clarification, collects 80% ethanol elution and concentrates, and lyophilization gets HT
W13.4g.
Embodiment 2
Ethyl acetate extract (HT
AE) and water soluble part W
2(HT
W2) preparation:
Get 80g and be ground into the dry Caulis Sargentodoxae stem about 20 orders, measure 80% ethanol 85 ℃ of following water-bath reflux, extract, twice for 10 times, each 2h, merge extractive liquid,, decompression recycling ethanol.The Caulis Sargentodoxae ethanol extraction is used aqueous dispersion, uses petroleum ether, dichloromethane, ethyl acetate extraction successively, and concentrating under reduced pressure reclaims solvent, obtains petroleum ether part, dichloromethane position, ethyl acetate extract, water position respectively.The water position concentrates after the HP-20 macroporous adsorbent resin, and first water is eluted to colourless, and reuse 95% ethanol elution is to colourless, collect 95% ethanol elution concentrate water soluble part W
2, lyophilization gets HT
AE2.62g, HT
W25.96g.
Embodiment 3
HT
PS, HT
W1, HT
AEAnd HT
W2Xylol causes the influence of mice ear reaction
Choose 80 of 20 ± 2g Kunming mouses, be divided into 10 groups at random, male and female half and half, 8 every group.The 1st group: 1% tween 80, blank group; The 2nd group: 25mg/kg indomethacin, positive controls; 3rd, 4 groups: HT
PSHigh low dose group (200mg/kg, 100mg/kg); 5th, 6 groups: HT
W1High low dose group (200mg/kg, 100mg/kg); 7th, 8 groups: HT
AEHigh low dose group (200mg/kg, 100mg/kg); 9th, 10 groups: HT
W2High low dose group (200mg/kg, 100mg/kg).Each organize mice with 20mL/kg gastric infusion 1h after; It is scorching that mouse right ear is coated with 50 μ L caused by dimethylbenzene xylene, after half an hour the dislocation of mice cervical vertebra put to death, and uses diameter the same position of ear to lay round auricle as the card punch of 7mm in the left and right sides; Analytical balance is weighed; The difference of auris dextra and left ear weight is the swelling degree, calculates inhibitory rate of intumesce, swelling degree (mg)=cause scorching back auris dextra weight-left ear weight.Inhibitory rate of intumesce=(the average swelling degree of the matched group-average swelling degree of administration the group)/average swelling degree of matched group * 100%, experimental result is seen table 1.Data show, HT
W2It is the strongest that the position suppresses the mice ear activity.
The influence of table 1 mice caused by dimethylbenzene xylene ear swelling (
n=8)
| No. | The animal group | Dosage (mg/kg) | Average swelling degree (mg) | Suppression ratio (%) |
| 1 | Blank control group | - | 10.9±4.9 | - |
| 2 | The indomethacin group | 25 | 2.2±1.4 | 30.92 |
| 3 | HT PS | 200 | 4.1±2.9 ** | 62.59 |
| 4 | HT PS | 100 | 7.5±3.6 | 30.92 |
| 5 | HT W1 | 200 | 6.0±3.0 * | 50.33 |
| 6 | HT W1 | 100 | 6.6±2.5 * | 44.95 |
| 7 | HT AE | 200 | 4.1±2.8 * | 61.79 |
| 8 | HT AE | 100 | 8.3±3.2 | 25.24 |
| 9 | HT W2 | 200 | 3.2±3.1 ** | 70.53 |
| 10 | HT W2 | 100 | 8.7±4.0 | 19.47 |
**p＜0.01，
*p＜0.05
Embodiment 4
HT
PS, HT
W1, HT
AEAnd HT
W2On Carrageenan causes the influence of normal rat paw swelling reaction and chooses 60 of 180-200g male SD rats, is divided into 10 groups at random, 6 every group.The 1st group: 1% tween 80, blank group; The 2nd group: 10mg/kg indomethacin, positive controls; 3rd, 4 groups: HT
PSHigh low dose group (100mg/kg, 50mg/kg); 5th, 6 groups: HT
W1High low dose group (100mg/kg, 50mg/kg); 7th, 8 groups: HT
AEHigh low dose group (100mg/kg, 50mg/kg); 9th, 10 groups: HT
W2High low dose group (100mg/kg, 50mg/kg).With 20mL/ (kgd) isometric(al) gastric infusion 1 time, 4d continuously.1h measures the sufficient pawl volume (mL) of mark under every the right back sufficient pawl ankle joint of rat upper end shank-feathering after the last administration; Tie-in 2 times; Average as causing scorching preceding initial volume; Give every rat right hind leg vola mind-set ankle joint direction inserting needle subcutaneous injection 1% carrageenin 0.1mL synchronously and cause inflammation, measure the sufficient pawl volume (mL) that causes mark under scorching back 1.0,2.0,3.0 and the 4.0h foot pawl ankle joint upper end shank-feathering respectively, the result sees table 2.Data show, remove HT
AEThe position, the inhibitory rate of intumesce of low dose group is more remarkable, wherein HT
W1It is the strongest that the position suppresses the swelling performance.
Swelling degree (ml)=to scorching metapedes volume-to scorching front foot volume
Inhibitory rate of intumesce (%)=(the average swelling degree of the matched group-average swelling degree of administration the group)/average swelling degree of matched group * 100%
Table 2 carrageenin causes the influence (
n=6) of rat paw edema degree reaction
**p＜0.0l，
*p＜0.05
Embodiment 5
HT
PS, HT
Wl, HT
AEAnd HT
W2On Carrageenan causes MDA and PGE in the rat swelling foot sole of the foot inflammation tissue
2Content influence
1) assay method of MDA in the scorching foot tissue:
According to embodiment 3, cause scorching 4h after, put to death rat, 0.5cm cuts at place inflammatory swelling enough on articulatio talocruralis; Weigh, shred after the peeling, place the normal saline (NS) of 5mL to soak 1h after, the scorching foot that will soak NS immerses in the 0.45mL0.5% trichloroacetic acid (TCA); Abandon scorching foot behind the 4h, add the hydrochloric acid 1.0mL of 0.1mol/L, add the 0.55mL0.67% thiobarbituricacid again after; Boiling water bath 20min adds the 2mLNS dilution, with the centrifugal 10min of 1000r/min; Getting supernatant is that the 532nm place measures its light absorption value in wavelength, and with this content of representing MDA, experimental result is seen table 3.The inflammation tissue receives the radical damage degree lower in each position high dose group of data declaration, wherein HT
W1It is the strongest that the protection inflammation tissue at position is avoided the radical damage ability.
2) prostaglandin (PGE in the scorching foot tissue
2) assay method:
The sufficient normal saline soak of above-mentioned inflammation is centrifugal, draw supernatant 0.3mL, add 0.5mol/KOH-methanol solution 2mL, at 50 ℃ of following isomerization 20min, be diluted to 5mL with methanol, be that the 278nm place measures its absorbance in wavelength.Represent PGE with the suitable absorbance of every gram inflammatory tissue
2Content, experimental result is seen table 3.Can know the inhibition PGE of low dose group by data
2The effect that produces is stronger, wherein HT
WlThe position suppression ratio is the most remarkable.
The result sees table 3.
Table 3 carrageenin causes MDA and PGE in the rat swelling foot inflammation tissue
2Content (
N=6)
| No. | Group | Dosage (mg/kg) | MDA | PGE 2 |
| 1 | Blank control group | ? | 0.574±0.011 | 0.356±0.019 |
| 2 | Positive group | 10 | 0.123±0.029 ** | 0.186±0.016 ** |
| 3 | HT PS | 100 | 0.199±0.014 ** | 0.280±0.015 ** |
| 4 | HT PS | 50 | 0.263±0.044 ** | 0.232±0.015 ** |
| 5 | HT W1 | 100 | 0.194±0.006 ** | 0.244±0.028 ** |
| 6 | HT W1 | 50 | 0.214±0.021 ** | 0.197±0.013 ** |
| 7 | HT AE | 100 | 0.206±0.025 ** | 0.318±0.012 * |
| 8 | HT AE | 50 | 0.264±0.041 ** | 0.233±0.016 ** |
| 9 | HT W2 | 100 | 0.197±0.046 ** | 0.251±0.014 ** |
| 10 | HT W2 | 50 | 0.25±0.028 ** | 0.209±0.017 ** |
**p<0.01，
*p<0.05
Embodiment 6
HT
PS, HT
W1, HT
AEAnd HT
W2Antioxidation activity in vitro is measured
1) mensuration of DPPH radical scavenging activity:
The alcoholic solution that adds 1.0mL 200 μ mol/DPPH in the Caulis Sargentodoxae extract solution of 1mL variable concentrations adds mix homogeneously behind 2.0mL 80% ethanol again, dark place place behind the 30min with ultraviolet spectrophotometer at the 517nm place mensuration light absorption value A
i, measure the alcoholic solution of 1.0mL DPPH and the light absorption value A of 3.0mL alcoholic solution mixed liquor simultaneously
oLight absorption value A with 3mL ethanol and 1.0mL sample mix liquid
j, clearance rate formula: clearance rate (%)=[1-(A
i-A
j)/A
0] * 100%.Data show, HT
W2And HT
AEIt is the strongest that the DPPH ability is removed at the position.
2) mensuration of reducing power:
1.0mL the Caulis Sargentodoxae extract solution of variable concentrations; Adding 2.5mLpH is 6.6 the phosphate buffer and 2.5mL 1% potassium ferricyanide; In 50 ℃ of water-baths, be incubated 20min behind the mix homogeneously, add 10% trichloroacetic acid 2.5mL mixing again, with 3000r/min centrifugalize 10min; Pipette supernatant 2.5mL in test tube, adding distil water 2.5mL and 0.1%FeCl
3Aqueous solution 0.5mL measures light absorption value in the 700nm place behind the normal-temperature reaction 10min, and light absorption value is high more, explains that the reproducibility of this reactant mixture is strong more.Do contrast with Vc, face with preceding and prepare with distilled water.Data show, HT
W2And HT
AEThe position reducing power is stronger, but obviously is weaker than Vc.
Four kinds of active sites of table 4 are removed the experiment of DPPH free radical ability
No tests;
*: the concentration of Vc is respectively 10,25,50 and 100 μ g/mL
Four kinds of active site reducing power experiments of table 5
Embodiment 7
HT
PS, HT
W1, HT
AEAnd HT
W2Antioxidation and activity of fighting against senium are measured in the body
According to embodiment 3, cause scorching 4h after, femoral artery is got blood behind the anesthetized rat, disconnected cervical vertebra is got liver after putting to death rat, with serum and liver homogenate tissue be stored in-20 ℃ to be measured, MDA content and SOD activity data see that table 6 result shows HT in serum and the liver organization
W1It is the strongest to avoid the radical damage ability in position removing free radical, the protection body inflammatory process.
Embodiment 8
Caulis Sargentodoxae ethyl acetate extract (HT
AE) preparation of capsule preparations
6g Caulis Sargentodoxae ethyl acetate extract (HT
AE) freeze-dried powder, add 3g soluble starch and 9mL70% ethanol, mixing, 60 ℃ of oven dry are pulverized.Process capsule by every 0.45g.
Embodiment 9
Caulis Sargentodoxae water soluble part W
2(HT
W2) preparation of injection
1.6g Caulis Sargentodoxae water soluble part W
2(HT
W2) freeze-dried powder, add the 40mL distilled water, be heated to 80 ℃, add 2% (v/v) benzyl alcohol, cross 0.22 μ m filter membrane behind the mix homogeneously, the clear and bright liquid embedding that obtains in the 2mL ampoule, steam sterilization 30min, subsequent use.
Table 6 carrageenin causes MDA in foot swelling rat blood serum and the liver organization, SOD, GSH-Px and CAT activity influence
**p<0.01，
*p<0.05。
Claims (5)
1. the method for preparing of Caulis Sargentodoxae polysaccharide and water soluble part, it is characterized in that carrying out according to following step: dry Caulis Sargentodoxae medical material is crushed to 20 order coarse powder; Powder is 100 ℃ of following water reflux, extract, twice, and each 3 hours, behind the extracting solution concentrating under reduced pressure; Add dehydrated alcohol; The deposition of spending the night under 4 ℃-20 ℃, the centrifugal 10-30 min of 3000 r/min, drying precipitated part gets the Caulis Sargentodoxae polysaccharide; The 1/30-1/5 of concentrated supernatant to original volume; Cross the HP-20 macroporous adsorbent resin, first water is washed till closely colourless, and the ethanol elution of reuse 2BV-10BV volume ratio 80%, flow velocity are 10-60 mL/min, and collected volume concentrates than 80% ethanol elution, and lyophilization gets water soluble part.
2. the method for preparing of Caulis Sargentodoxae polysaccharide according to claim 1 and water soluble part; It is characterized in that carrying out according to following step: dry Caulis Sargentodoxae medical material, be crushed to 20 order coarse powder, powder is twice of 100 ℃ of following water reflux, extract; Each 3 hours; Behind the extracting solution concentrating under reduced pressure, add dehydrated alcohol, the deposition of spending the night under 5-15 ℃; The centrifugal 15-20 min of 3000 r/min; Drying precipitated part gets the Caulis Sargentodoxae polysaccharide; The 1/20-1/10 of concentrated supernatant to original volume; Cross the HP-20 macroporous adsorbent resin, first water is washed till closely colourless, reuse 4BV-6BV volume ratio 80% ethanol elution, and flow velocity is 20-30 mL/min; Collected volume concentrates than 80% ethanol elution, and lyophilization gets water soluble part.
3. the method for preparing of Caulis Sargentodoxae ethyl acetate extract and water soluble part is characterized in that carrying out according to following step: adding 8-12 volume ratio 50%-80% alcohol reflux doubly in the Caulis Sargentodoxae medicinal powder, and filtered and recycled ethanol; The Caulis Sargentodoxae ethanol extraction is used aqueous dispersion, uses petroleum ether, dichloromethane, ethyl acetate fractional extraction successively, and concentrating under reduced pressure reclaims solvent, obtains petroleum ether part, dichloromethane position, ethyl acetate extract, water position respectively; The water position is concentrated into the 1/30-1/10 of original volume; Cross the HP-20 macroporous adsorbent resin, first water is washed till closely colourless, reuse 2BV-10BV volume ratio 95% ethanol elution, and flow velocity is 10-60 mL/min; Collect 95% ethanol elution, concentrate water soluble part.
4. the method for preparing of Caulis Sargentodoxae ethyl acetate extract according to claim 3 and water soluble part is characterized in that the water position is concentrated into the 1/20-1/15 of original volume; Cross the HP-20 macroporous adsorbent resin, with 4BV-6BV volume ratio 95% ethanol elution, flow velocity is 20-30 mL/min.
5. claim 1,2,3 or 4 said four positions are used to prepare the purposes of anti inflammatory immunity and antiaging agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210180781.8A CN102697822B (en) | 2012-06-04 | 2012-06-04 | Application of sargentg loryvine stem active fraction to preparation of anti-inflammatory-immune and anti-ageing medicaments |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210180781.8A CN102697822B (en) | 2012-06-04 | 2012-06-04 | Application of sargentg loryvine stem active fraction to preparation of anti-inflammatory-immune and anti-ageing medicaments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102697822A true CN102697822A (en) | 2012-10-03 |
| CN102697822B CN102697822B (en) | 2014-04-09 |
Family
ID=46891069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210180781.8A Expired - Fee Related CN102697822B (en) | 2012-06-04 | 2012-06-04 | Application of sargentg loryvine stem active fraction to preparation of anti-inflammatory-immune and anti-ageing medicaments |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102697822B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104922172A (en) * | 2015-06-08 | 2015-09-23 | 贵州大学 | Application and extraction method of sargentgloryvine stem extract |
| CN108125964A (en) * | 2018-01-31 | 2018-06-08 | 西南大学 | δ-amyrenone or the application with δ-amyrenone extract as main component in the drug for preparing protection hepatic injury |
| CN108853176A (en) * | 2018-07-10 | 2018-11-23 | 广西民族大学 | A kind of concocting method effectively extracted for Caulis Spatholobi drug effect |
| CN117379378A (en) * | 2023-12-07 | 2024-01-12 | 山东金瑞生物科技有限公司 | Compound amoxicillin soluble powder for livestock and preparation process thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1781526A (en) * | 2004-12-03 | 2006-06-07 | 江西仁和（集团）发展有限公司 | Method for preparing medicine |
| CN101879221A (en) * | 2010-06-30 | 2010-11-10 | 南京中医药大学 | Medical application of caulis polygoni multiflori |
-
2012
- 2012-06-04 CN CN201210180781.8A patent/CN102697822B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1781526A (en) * | 2004-12-03 | 2006-06-07 | 江西仁和（集团）发展有限公司 | Method for preparing medicine |
| CN101879221A (en) * | 2010-06-30 | 2010-11-10 | 南京中医药大学 | Medical application of caulis polygoni multiflori |
Non-Patent Citations (2)
| Title |
|---|
| TANG JIAN 等: "《Chemical constituents from the water-soluble fraction of wild Sargentodoxa cuneata》", 《CHINESE JOURNAL LF NATURAL MEDICINES》 * |
| 倪士峰，等: "《大血藤化学成分及药学研究进展》", 《中国野生植物资源》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104922172A (en) * | 2015-06-08 | 2015-09-23 | 贵州大学 | Application and extraction method of sargentgloryvine stem extract |
| CN108125964A (en) * | 2018-01-31 | 2018-06-08 | 西南大学 | δ-amyrenone or the application with δ-amyrenone extract as main component in the drug for preparing protection hepatic injury |
| CN108853176A (en) * | 2018-07-10 | 2018-11-23 | 广西民族大学 | A kind of concocting method effectively extracted for Caulis Spatholobi drug effect |
| CN117379378A (en) * | 2023-12-07 | 2024-01-12 | 山东金瑞生物科技有限公司 | Compound amoxicillin soluble powder for livestock and preparation process thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102697822B (en) | 2014-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Song et al. | Applications, phytochemistry, pharmacological effects, pharmacokinetics, toxicity of Scutellaria baicalensis Georgi. and its probably potential therapeutic effects on COVID-19: a review | |
| Erpel et al. | Phlorotannins: From isolation and structural characterization, to the evaluation of their antidiabetic and anticancer potential | |
| Ríos | Chemical constituents and pharmacological properties of Poria cocos | |
| CN102697822B (en) | Application of sargentg loryvine stem active fraction to preparation of anti-inflammatory-immune and anti-ageing medicaments | |
| CN100500196C (en) | Method for preparing paris polyphylla total saponin | |
| CN106065023A (en) | Hydrolysable tannin compounds, its medical composition and its use | |
| CN100500160C (en) | Medicinal composition containing epimedium active constituent and its application | |
| CN102617698B (en) | Method for preparing fine dioscin and application of fine dioscin | |
| CN102875615B (en) | Extraction method and application of falcate dolichos root or leaf glucoside A and total saponins of falcate dolichos root or leaf | |
| CN101708193B (en) | Pharmaceutical composition of triptolide-containing medicine and bracken and preparation and application thereof | |
| CN102731276A (en) | Diterpene compound possessing antitumor activity, preparation method thereof and application thereof | |
| CN103739653B (en) | A kind of 23-fall oleanane acid compound and preparation method thereof and the purposes in preparing glycosidase inhibitor | |
| CN107383150B (en) | A kind of compound and its preparation method and application with antihepatitis activity | |
| CN101040891B (en) | Method of preparing tripterygium hypoglaucum (Levl) hutch alkaloids | |
| CN102793729A (en) | Triptolide and chinese brake herb general flavone combined medicinal composition and preparation and application thereof | |
| CN101416970A (en) | Use of arjunolic acid in preparing glycosidase inhibitor | |
| CN102000046B (en) | Application of antrodia camphorata cyclohexenone compound in preparing medicine for inhibiting growth of pancreatic cancer tumor cells | |
| CN102295678B (en) | Purpose of triterpenoid-saponin compound extracted form anemone taipaiensis | |
| CN102139072A (en) | Chinese medicinal preparation for treating gynecological inflammation | |
| CN102675252B (en) | There is Cesong alkyl type diterpine compound and the application thereof of anti-tumor activity | |
| CN101897766B (en) | Anti-inflammatory and analgesic medicine composition as well as preparation method and application thereof | |
| CN104529968B (en) | Anti-tumor diterpenoid compound, and pharmaceutical composition, preparation method and application thereof | |
| CN103446220B (en) | Herba Artemisiae Annuae Radix Tripterygii Wilfordii medicine is to composition of medicine, preparation method and application | |
| Wang et al. | Modern research progress on extraction and purification, pharmacological activity, toxicology, pharmacokinetics and carrier new dosage forms of ophiopogonin | |
| CN101474315A (en) | Effective component group of stem-bark or root-bark of Daphne giraldii as well as preparation method and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140409 Termination date: 20190604 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |